Literature DB >> 21343555

Importance of expert central review in the diagnosis of lymphoid malignancies in a regional cancer network.

Ian E Proctor1, Christopher McNamara, Manuel Rodriguez-Justo, Peter G Isaacson, Alan Ramsay.   

Abstract

PURPOSE: The accurate diagnosis of hematologic malignancies remains a challenging area for histopathologists. In 2003, the North Central London Lymphoma network was established to provide a centralized expert review service for general histopathologists based in peripheral nonspecialist hospitals. By studying samples sent for review, we sought to assess the diagnostic and clinical impact of centralized expert review in lymphoma diagnosis.
METHODS: A total of 1,949 patient samples were subject to expert review between 2003 and 2008. Diagnostic discordance rates were identified after expert review, and the impact on patient management was assessed by a hematologic oncology specialist.
RESULTS: An overall discordance rate of 27.3% was identified. Among the 10 most commonly referred lymphoid malignancies, the discordance rate varied between 3.6% and 34.1%. A small but significant number of reactive (n = 17) and malignant (n = 5) discordant diagnoses were also identified. Expert central review resulted in a major change to patient management in 2.1% of patients and prevented delays in treatment in 9.3% of patients. During the 6-year study, the discordance rate improved significantly, decreasing from 32% to 13%. Although centralized review incurred additional costs, these were relatively small compared with the costs associated with treatment.
CONCLUSION: This retrospective study demonstrates the importance of expert central review in the accurate diagnosis and timely management of lymphoid malignancies. Furthermore, it shows that where full centralization of services is not viable, a network comprising nonspecialist hospitals linked to a center providing expert review is a practical alternative to full unification of services at a single location and can help prevent local deskilling.

Entities:  

Mesh:

Year:  2011        PMID: 21343555     DOI: 10.1200/JCO.2010.31.2223

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  16 in total

1.  Contributions of Subtypes of Non-Hodgkin Lymphoma to Mortality Trends.

Authors:  Nadia Howlader; Lindsay M Morton; Eric J Feuer; Caroline Besson; Eric A Engels
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-10-15       Impact factor: 4.254

2.  Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study.

Authors:  Patrizia Mondello; Normann Steiner; Wolfgang Willenbacher; Claudio Cerchione; Davide Nappi; Endri Mauro; Simone Ferrero; Salvatore Cuzzocrea; Michael Mian
Journal:  Oncologist       Date:  2018-01-09

3.  A collaborative nationwide lymphoma study in Lebanon: incidence of various subtypes and analysis of associations with viruses.

Authors:  Zaher K Otrock; Jad Saab; Georges Aftimos; Fady Nasr; Fadi S Farhat; Saad Khairallah; Gérard Abadjian; Marwan Ghosn; Hassan Sidani; Ahmad Ibrahim; Ayman Tawil; Claude Ghorra; Zarouhie Meguerian; Walid Mokaddem; Walid Dayeh; Ziad Salem; Georges Chahine; Nizar Bitar; Anas Mugharbel; Joseph Makdessi; Christina Khater; Mirna El Hajj; Dany Abi Gerges; Charles Sfeir; Joseph Kattan; Khaled Ibrahim; Michel Saade; Hussein Sadek; Rami A Mahfouz; Mohamed A Kharfan-Dabaja; Ghazi Zaatari; Ali Bazarbachi
Journal:  Pathol Oncol Res       Date:  2013-05-08       Impact factor: 3.201

4.  General Biomarker Recommendations for Lymphoma.

Authors:  Lisa Rimsza; Yuri Fedoriw; Louis M Staudt; Ari Melnick; Randy Gascoyne; Michael Crump; Lawrence Baizer; Kai Fu; Eric Hsi; John W C Chan; Lisa McShane; John P Leonard; Brad S Kahl; Richard F Little; Jonathan W Friedberg; Lale Kostakoglu
Journal:  J Natl Cancer Inst       Date:  2016-12-16       Impact factor: 13.506

5.  Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer Network.

Authors:  Alex F Herrera; Allison Crosby-Thompson; Jonathan W Friedberg; Gregory A Abel; Myron S Czuczman; Leo I Gordon; Mark S Kaminski; Michael M Millenson; Auayporn P Nademanee; Joyce C Niland; Scott J Rodig; Maria A Rodriguez; Andrew D Zelenetz; Ann S LaCasce
Journal:  Cancer       Date:  2014-04-04       Impact factor: 6.860

6.  Agreement between diagnoses of childhood lymphoma assigned in Uganda and by an international reference laboratory.

Authors:  Jackson Orem; Sven Sandin; Caroline E Weibull; Michael Odida; Henry Wabinga; Edward Mbidde; Fred Wabwire-Mangen; Chris Jlm Meijer; Jaap M Middeldorp; Elisabete Weiderpass
Journal:  Clin Epidemiol       Date:  2012-12-14       Impact factor: 4.790

7.  Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine era.

Authors:  Rebecca L King; Grzegorz S Nowakowski; Thomas E Witzig; David W Scott; Richard F Little; Fangxin Hong; Randy D Gascoyne; Brad S Kahl; William R Macon
Journal:  Blood Cancer J       Date:  2018-02-28       Impact factor: 11.037

8.  Time Trends in Rates of Hodgkin Lymphoma Histologic Subtypes: True Incidence Changes or Evolving Diagnostic Practice?

Authors:  Sally L Glaser; Christina A Clarke; Theresa H M Keegan; Ellen T Chang; Dennis D Weisenburger
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-07-27       Impact factor: 4.090

9.  Discrepancies in Lymphoma Diagnosis Over the Years: A 13-Year Experience in a Tertiary Center.

Authors:  Neval Özkaya; Nuray Başsüllü; Ahu Senem Demiröz; Nükhet Tüzüner
Journal:  Turk J Haematol       Date:  2016-12-12       Impact factor: 1.831

10.  Expert central review in lymphoma diagnosis. Is there a need?

Authors:  Camille Laurent; Philippe Gaulard; Pierre Brousset
Journal:  Oncotarget       Date:  2017-12-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.